NCT03549000 2024-12-13
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
Novartis
Lisata Therapeutics, Inc.
Nykode Therapeutics ASA
National Vaccine and Serum Institute, China
Immune Cell, Inc.
Immune Cell, Inc.